2019
DOI: 10.1101/836932
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1

Abstract: YEATS-domain-containing MLLT1 is an acetyl/acyl-lysine reader domain, which is structurally distinct from well-studied bromodomains and has been strongly associated in development of cancer. Here, we characterized piperazine-urea derivatives as an acetyl/acyl-lysine mimetic moiety for MLLT1. Crystal structures revealed distinct interaction mechanisms of this chemotype compared to the recently described benzimidazole-amide based inhibitors, exploiting different binding pockets within the protein. Thus, the pipe… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 37 publications
0
2
0
Order By: Relevance
“…Peptidomimetic inhibitors and chemical probes for the AF9 YEATS domain and the closely related ENL YEATS domain that bind with nanomolar affinities have been reported, with the most potent compound replacing the alkene of the crotonyl group with an oxazole moiety 30–32 . Additionally, several groups have reported small molecule inhibitors of AF9 and ENL 33–39 . However, no inhibitor studies to date have evaluated how binding is affected when an amide is replaced with an amide isostere.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Peptidomimetic inhibitors and chemical probes for the AF9 YEATS domain and the closely related ENL YEATS domain that bind with nanomolar affinities have been reported, with the most potent compound replacing the alkene of the crotonyl group with an oxazole moiety 30–32 . Additionally, several groups have reported small molecule inhibitors of AF9 and ENL 33–39 . However, no inhibitor studies to date have evaluated how binding is affected when an amide is replaced with an amide isostere.…”
Section: Introductionmentioning
confidence: 99%
“…[30][31][32] Additionally, several groups have reported small molecule inhibitors of AF9 and ENL. [33][34][35][36][37][38][39] However, no inhibitor studies to date have evaluated how binding is affected when an amide is replaced with an amide isostere.…”
mentioning
confidence: 99%